Company behind Pfizer vaccine expected to file results of trial of five- to 11-year-olds with regulator soon
The German company BioNTech, which developed the Pfizer vaccine, expects to seek approval from regulators for Covid jabs suited for younger children as early as mid-October, its founders have said.
“Already over the next few weeks we will file the results of our trial in five- to 11-year-olds with regulators across the world and will request approval of the vaccine in this age group, also here in Europe,” BioNTech’s chief medical officer, Özlem Türeci, told the German news magazine Der Spiegel.
